CeleCor Therapeutics Submitted Zalunfiban Application
The company completed its FDA submission for a drug designed to treat specific types of heart attacks.
Updated on Sept. 23, 2026 in Heart Disease
Live Poll
Do you trust that new drug breakthroughs will improve emergency heart care in your area?
On June 24, 2026, CeleCor Therapeutics submitted the final section of its New Drug Application to the FDA for zalunfiban. The drug is intended to treat ST-segment elevation heart attacks via subcutaneous injection.
Why it matters
The FDA submission follows a Rolling Review process granted in January 2026, which allows regulators to evaluate data incrementally to shorten the overall review timeline. The application aims to bring a new treatment option to patients at the first point of medical contact during a heart attack.
CeleCor Therapeutics completed Phase 3 clinical testing of zalunfiban, which were subsequently published in The New England Journal of Medicine Evidence. The trial evaluated the efficacy of the drug for patients experiencing ST-segment elevation heart attacks.
The players
CeleCor Therapeutics
A pharmaceutical company headquartered in Del Mar, California, focused on developing cardiovascular therapies.
Food and Drug Administration
The federal agency responsible for regulating new drug applications and ensuring the safety of pharmaceutical products in the United States.
Michael Moye
The newly appointed Chief Commercial Officer at CeleCor Therapeutics tasked with leading commercial operations for zalunfiban.
The details
Zalunfiban is designed for administration via subcutaneous injection immediately upon the first point of medical contact for patients. To prepare for the potential market launch, CeleCor Therapeutics appointed Michael Moye as the company's new Chief Commercial Officer to oversee strategy and operations.
Timeline
November 2025: Phase 3 results were presented at the American Heart Association Scientific Sessions.
January 2026: Zalunfiban was granted FDA Rolling Review status.
June 24, 2026: CeleCor Therapeutics submitted the final New Drug Application section.
The Big Picture
The application for zalunfiban follows the standard FDA Fast Track designation process used for medical breakthroughs. This submission aligns with the wider industry trend of utilizing regulatory pathways to accelerate the availability of life-saving heart attack treatments.
If approved, zalunfiban could provide a new injectable treatment option for patients during the critical window of a heart attack. The appointment of a Chief Commercial Officer suggests the company is preparing for potential distribution and availability of the drug in the near future.
The takeaway
The submission of the final application marks a milestone in the development of zalunfiban following positive Phase 3 clinical data. Patients and healthcare providers should monitor regulatory updates to see when this treatment might become available for emergency use.
Further reading
Learn more about ongoing research into Heart Disease and current treatment standards.
Source note: This article includes information reported by Drugs.
Live Poll
Do you trust that new drug breakthroughs will improve emergency heart care in your area?
